These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 29080066)

  • 1. Choosing First-Line Biologic Treatment for Moderate-to-Severe Psoriasis: What Does the Evidence Say?
    Amin M; No DJ; Egeberg A; Wu JJ
    Am J Clin Dermatol; 2018 Feb; 19(1):1-13. PubMed ID: 29080066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.
    Thatiparthi A; Martin A; Liu J; Egeberg A; Wu JJ
    Am J Clin Dermatol; 2021 Jul; 22(4):425-442. PubMed ID: 33861409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: Results from the Corrona Psoriasis Registry.
    Strober B; Karki C; Mason M; Guo N; Holmgren SH; Greenberg JD; Lebwohl M
    J Am Acad Dermatol; 2018 Feb; 78(2):323-332. PubMed ID: 29051036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of IL-23 Inhibitors for the Treatment of Plaque Psoriasis and Psoriatic Arthritis: A Comprehensive Review.
    Yang K; Oak ASW; Elewski BE
    Am J Clin Dermatol; 2021 Mar; 22(2):173-192. PubMed ID: 33301128
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetics and Pharmacogenomics in Moderate-to-Severe Psoriasis.
    Ovejero-Benito MC; Muñoz-Aceituno E; Reolid A; Saiz-Rodríguez M; Abad-Santos F; Daudén E
    Am J Clin Dermatol; 2018 Apr; 19(2):209-222. PubMed ID: 28921458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologics and Psoriasis: The Beat Goes On.
    Kim HJ; Lebwohl MG
    Dermatol Clin; 2019 Jan; 37(1):29-36. PubMed ID: 30466686
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Safety and Efficacy of Tumor Necrosis Factor Inhibitors and Interleukin-17 Inhibitors in Patients With Psoriasis.
    Green LJ; Yamauchi PS; Kircik LH
    J Drugs Dermatol; 2019 Aug; 18(8):776-788. PubMed ID: 31424708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors associated with the choice of the first biologic in psoriasis: real-life analysis from the Psobioteq cohort.
    Sbidian E; Giboin C; Bachelez H; Paul C; Beylot-Barry M; Dupuy A; Viguier M; Lacour JP; Schmutz JL; Bravard P; Mahé E; Beneton N; Misery L; Delaporte E; Modiano P; Barbarot S; Regnier E; Jullien D; Richard MA; Joly P; Tubach F; Chosidow O
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2046-2054. PubMed ID: 28609574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies.
    Lasagni C; Bigi L; Conti A; Pellacani G
    J Dermatolog Treat; 2018; 29(sup2):5-8. PubMed ID: 30403898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors.
    Gaspari AA; Tyring S
    Dermatol Ther; 2015; 28(4):179-93. PubMed ID: 26201310
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities.
    Jiang Y; Chen Y; Yu Q; Shi Y
    BioDrugs; 2023 Jan; 37(1):35-55. PubMed ID: 36592323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tailored treatment options for patients with psoriatic arthritis and psoriasis: review of established and new biologic and small molecule therapies.
    Elyoussfi S; Thomas BJ; Ciurtin C
    Rheumatol Int; 2016 May; 36(5):603-12. PubMed ID: 26892034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-immune functions of inflammatory cytokines targeted by anti-psoriatic biologics: a review.
    Lee TL; Tsai TF
    Inflamm Res; 2022 Feb; 71(2):157-168. PubMed ID: 34981130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guselkumab for the Treatment of Psoriasis.
    Machado Á; Torres T
    BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment.
    Ten Bergen LL; Petrovic A; Krogh Aarebrot A; Appel S
    Scand J Immunol; 2020 Oct; 92(4):e12946. PubMed ID: 32697374
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New biologics in psoriasis: an update on IL-23 and IL-17 inhibitors.
    Dong J; Goldenberg G
    Cutis; 2017 Feb; 99(2):123-127. PubMed ID: 28319618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
    Jeon C; Sekhon S; Yan D; Afifi L; Nakamura M; Bhutani T
    Hum Vaccin Immunother; 2017 Oct; 13(10):2247-2259. PubMed ID: 28825875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New biologics for psoriasis and psoriatic arthritis.
    Rozenblit M; Lebwohl M
    Dermatol Ther; 2009; 22(1):56-60. PubMed ID: 19222517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.
    Medina-Gil C; Dehesa L; Vega A; Kerdel F
    Int J Dermatol; 2015 Jul; 54(7):846-52. PubMed ID: 26108266
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.